UBS has upgraded Sanofi to a 'Buy' rating with a target price of 110 euros, citing the neurodermatitis drug Dupixent as a key growth driver for the company in the third quarter. Analyst Carl Walton anticipates that growth will accelerate further in 2025.
UBS has upgraded its rating for Sanofi to "Buy," setting a target price of 110 euros. Analyst Carl Walton highlighted that the neurodermatitis drug Dupixent is expected to drive growth for the company in the third quarter, with acceleration anticipated in 2025.
UBS has maintained a "Buy" rating for Sanofi, setting a price target of 110 euros ahead of the company's upcoming financial results. Analyst Carl Walton highlighted that the neurodermatitis drug Dupixent is expected to drive growth for the pharmaceutical firm in the third quarter, with acceleration anticipated in 2025.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
